Skip to main content
HomeInvestors hubNews
alt text

Latest investmentnews

Stock exchange notices

Investor news

PRESS-RELEASE
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
Oslo, Norway
18 May 2026
OSE Notice
Photocure ASA: Results for the first quarter of 2026
Oslo, Norway
7 May 2026
PRESS-RELEASE
New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
Oslo, Norway
4 May 2026
PRESS-RELEASE
Photocure ASA: Invitation to presentation of first quarter 2026 financial results
Oslo, Norway
30 April 2026
OSE Notice
Photocure ASA: Annual Report 2025
Oslo, Norway
27 April 2026
OSE Notice
Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals
Oslo, Norway
20 April 2026
NEWS POST
Asieris publishes Annual Report and shares Market approval of Richard Wolf System blue equipment in China
Oslo, Norway
17 April 2026
OSE Notice
Photocure ASA: Update on Regulatory Classification for OAY Equipment
Oslo, Norway
13 April 2026
NEWS POST
Blue Light Cystoscopy demonstrates cost neutrality through reduced recurrence in real-world BRAVO study
Oslo, Norway
7 April 2026
NEWS POST
Update on KARL STORZ’s Citizen Petition
Oslo, Norway
28 March 2026
NEWS POST
Asieris: Cevira Endorsed with Level 1A Evidence in Expert Consensus
Oslo, Norway
25 March 2026
PRESS-RELEASE
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
Oslo, Norway
16 March 2026
PRESS-RELEASE
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Oslo, Norway
3 March 2026
PRESS-RELEASE
Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe
Oslo, Norway
27 February 2026
OSE Notice
Photocure ASA: Results for the fourth quarter of 2025
Oslo, Norway
18 February 2026
OSE Notice
Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results
Oslo, Norway
11 February 2026